News - Events

Make sure you meet with us and discuss your projects and demands as well as new developments and service opportunities in person!

Please contact Luca Covello to arrange a meeting prior to the show.

Forthcoming Events

  • CPhI North America, May 16-18, 2017 Pennsylvania Convention Center Philadelphia, PA, USA (BOOTH 2253)
  • CF@BO 2017, June 4-6, 2017 Bologna, Italy
  • CPhI Worldwide, 24 - 26 October 2017 Messe Frankfurt, Germany  (STAND No: 40B40)

order by visits date title

Controlled Substances Studies & Analysis

PolyCrystalLine received the authorization N°487/2016 from the Italian Ministry of Healthfor the study and chemical/physical analysis of controlled substances. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for clients with complex chemistry challenges.

Read all

Highly Potent API

Polycrystalline is expanding its HPAPI offerings, up to OEB 5 level of containment for the synthesis, study and development of anti-cancer and cytotoxic APIs. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for clients with complex chemistry challenges.

Read all

Des-Methyl-Venlafaxine Salt

  New Crystalline Forms of Des-Methyl-Venlafaxine Salt Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Pristiq (desvenlafaxine succinate). This DEP001 product is expected to enter the US market at least three years before any other generic desvenlafaxine products enter the market. Pristiq sales are projected to exceed one billion dollars yearly. Pristiq was approved in 2008 by Wyeth Pharmaceuticals for the treatment of major depres

Read all

Polymorphs of Dex-Lansoprazole

  New Crystalline Forms of Dex-Lansoprazole Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Kapidex (dexlansoprazole). This DEP002 product contains a new and stable crystal of dexlansoprazole which circumvents Takeda’s intellectual property. Kapidex is a proton pump inhibitor that obtained FDA approval in 2009 by Takeda Pharmaceuticals for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GE

Read all

8th CRYSTAL FORMS@BO CONVENTION

The 8th Bologna Convention on Crystal Forms Crystals in Food & Pharma - CF@BO 14-16 June 2015, Bologna, Italy OPENING - SUNDAY AT 2.00 pm - CHEMISTRY DEP. "G. CIAMICIAN" - Via Selmi, 2 - 40126 - Bologna. The AIC is supporting the registration to the workshop for two students and AIC members. Those willing to ask for a grant are kindly requested to send before April 15th, 2015 their CV and motivations to l.maini@unibo.it. REGISTRATION OPEN - Click Here FEES and VENUE - Click Here PROGRAMME - Click Here

Read all

FRENCH CERTIFICATION

  PolyCrystalLine s.r.l. received the approval from French Health Ministry as a CRO for R&D activities, the French companies who use our services can benefit of a tax credit in compliance with the article 244 quater B of the French general code of taxes. (see the PDF attached)  

Read all

GMP CERTIFICATION

  PolyCrystalLine received the audit from the Health Agency for the cGMP certification. The authorization is granted on chemical/physics analyses for qualitative and quantitative determination of active ingredients, intermediates and finished products   

Read all

Pagina 1 di 2
© Copyright Polycrystalline SpA - All rights reserved - VAT IT02600021204 / powered by DibiWeb